Referral for COVID-19 Outpatient Therapy



INSTRUCTIONS TO PROVIDER: Available treatments include injectable monoclonal antibodies and oral agents that have received Emergency Use Authorization (EUA) from the FDA. To refer a patient, complete all portions of this form. Fax it along with the prescription; lab-confirmed SARS-CoV-2 viral test results (not required if testing performed by KDMC); patient demographic sheet; and current medication list (required for Paxlovid) to the KDMC Infusion Center at **(606) 408-6724**. You must provide complete documentation as indicated. Referrals missing information or documentation will not be reviewed and may result in the patient being ineligible for treatment.

| Ordering Provider: | Date: | |
|---|--|--|
| Ordering Provider's Phone: | FAX: | |
| Patient's Name: | DOB: | Age: |
| Date of Onset: | Test Date: (Lab-confirmed SARS-Co | V-2 viral test required) |
| RISK FACTORS FOR SEVERE ILLNESS PRIORIT Immunocompromised (specify): Cardiovascular Disease (specify): Chronic Kidney Disease/Stage: Chronic Respiratory Disease (specify): Diabetes BMI of 30-35 (specify): | | |
| PAXLOVID REFERRALS A list of current medications must be included with this referral. Patients cannot be considered for Paxlovid without a current medication list. Paxlovid is contraindicated in patients taking the following: • Antibiotics: rifampin, rifapentine clozapine, quetiapine, lumateperone • Miscellaneous: eplerenone, finerenone, | | |
| Antiarrhythmics: amiodarone, disopyramide, dofetilide, dronedarone, propafenone, flecainide, mexilitine, quinidine Anticoagulants: Anxiolytics: triaz Ergot alkaloids: ergoloid mesylate ergotamine, meth | dabigatran, rivaroxaban apalutamide, bose olam, midazolam ivabradine, lonafa dihydroergotamine, St. John's Wort, vo es, ergonovine, chemotherapy or | entan, domperidone, rnib, lomitapide, |
| □ I have reviewed the patient's medication list and have ve medications. | ified the patient is not currently taking any | of the contraindicated |
| OXYGEN USE | | |
| The patient was not on oxygen at baseline and did no The patient was on oxygen at baseline and did require Baseline O²: | oxygen at the time of this clinical evaluation | on. |
| Patient's Vaccination Status: Unvaccinated Vac | cinated 🗌 Vaccinated + Booster | |
| Discussed with patient/caregiver that the patient meets | | |

mild-to-moderate COVID-19. Monoclonal antibodies will be administered based on availability, per King's Daughters Pharmacy & Therapeutic Approved Guidelines.

The patient/caregiver was directed to the online patient and caregiver fact sheet; was informed that current COVID-19 treatments are unapproved drug(s) that have received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration; was informed of the potential risks and benefits of such therapy; and was informed of alternative treatments.

PROVIDER SIGNATURE: